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Objectives: We have shown that exhaled nitric oxide levels decrease after surgical
closure of congenital left-to-right cardiac shunts. It remains unclear whether the
change in exhaled nitric oxide levels reflects endothelial injury caused by the use of
cardiopulmonary bypass or the decrease in pulmonary blood flow attendant on shunt
closure. Transcatheter atrial septal defect closure permits shunt closure without the
use of cardiopulmonary bypass. Therefore we compared changes in exhaled nitric
oxide levels after surgical and transcatheter device closure of atrial septal defects.
Methods: We enrolled sequentially 30 children undergoing atrial septal defect
closure. Fifteen patients (age range, 0.4-16 years; median age, 6.5 years) underwent
surgical atrial septal defect closure with cardiopulmonary bypass, and 15 patients
(age range, 4-17 years; median age, 8.4 years) had device closure of the atrial septal
defect in the catheterization laboratory. We measured nitric oxide levels in end-tidal
expiratory gas with a rapid-response chemiluminescent analyzer before and after
atrial septal defect closure.
Results: After surgical repair of the atrial septal defect, exhaled nitric oxide
decreased by 21%, from 10.9  4.4 to 8.4  3.3 ppb (P  .005), whereas after
transcatheter defect closure, exhaled nitric oxide increased by 23%, from 7.6  2.6
to 9.3  3.7 ppb (P  .005). Hemoglobin levels in patients undergoing surgical
intervention were significantly lower (P  .0001) postoperatively.
Conclusions: We confirmed that exhaled nitric oxide, despite a fall in hemoglobin,
decreases after surgical closure of atrial septal defects. In contrast, exhaled nitric
oxide levels increase after transcatheter closure. Exhaled nitric oxide levels may
reflect bypass-induced endothelial cell injury and are independent of changes in
pulmonary blood flow.
Nitric oxide (NO), synthesized by the vascular endothelium, playsa central role in the regulation of pulmonary vascular tone beforeand after correction of congenital heart defects.1,2 The pulmonaryvascular endothelium may be injured by the shear stress imposedby congenital left-to-right shunts or cardiopulmonary bypass(CPB) necessary for the surgical repair. Endothelial injury and
impaired production of NO may be implicated in the increased pulmonary vascular
resistance encountered after CPB.2 This may explain the efficacy of inhaled NO in
the treatment of pulmonary hypertension and reperfusion injury.1,3 We have dem-
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onstrated previously that exhaled NO levels decrease after
surgical closure of left-to-right intracardiac shunts in chil-
dren.4 The decrease in exhaled NO could reflect either
CPB-induced endothelial cell injury or a decrease in pul-
monary blood flow consequent on shunt closure.
Transcatheter device closure of atrial septal defects
(ASDs) makes it possible to close intracardiac shunts with-
out the use of CPB and thus discriminate between the effect
of CPB and changes in pulmonary blood flow. Therefore we
compared exhaled NO levels before and after ASD closure
in patients scheduled for surgical or transcatheter ASD
closure.
Patients and Methods
We enrolled sequentially 30 children (Table 1) with ASDs under-
going surgical closure with CPB (n  15) or by means of device
closure (n  15) in the catheterization laboratory. The method of
ASD closure was decided by the referring cardiologist after dis-
cussion with the family. However, 6 patients were referred for
surgical ASD closure for reasons that excluded transcatheter ASD
closure. Three patients had isolated primum ASDs, 2 patients
weighed less than 10 kg, and 3 patients had defects considered
unsuitable for transcatheter closure at the time (1 patient had a
fenestrated defect, in 1 patient the ASD was 20 mm, and in 1
patient the rim of the ASD was considered too deficient). No
patient was treated with glucocorticosteroids, nitrovasodilators,
L-arginine, or inhaled or intravenous NO synthase inhibitors
known to affect NO metabolism before or during the procedure.
Anesthetic management included the administration of thiopen-
tone, fentanyl, midazolam, muscle relaxants, and 1% isoflurane.
The isoflurane was interrupted for 15 minutes before sampling for
exhaled NO. The differences between the drugs administered to
the surgical ASD closure group were muscle relaxation with
pancuronium (vs rocuronium) and higher doses of fentanyl (12 
8 vs 3  3 g/kg) and protamine.
Ventilator settings were kept constant before and after ASD
closure, and the fraction of inspired oxygen was adjusted to be-
tween 0.25 and 0.3 for 15 minutes before NO sampling.
Surgical Closure
All patients received 300 U/kg heparin. CPB was performed with
systemic cooling between 32°C and 35°C with bicaval and ascend-
ing aorta cannulation. Cool cardioplegia was administered through
the aortic root in 11 cases performed with myocardial arrest. ASD
closure was performed with ventricular fibrillation in 4 cases.
Thirteen ASDs were closed with a patch, and 2 were closed by
means of direct suture.
Exhaled gas samples were collected immediately before can-
nulation and 30 minutes after discontinuation of CPB. Arterial
blood gas levels (including pH, PO2, and PCO2), end-tidal carbon
dioxide (except during sampling times), hemoglobin levels, heart
rate, systemic blood pressure, and rectal temperature were mea-
sured at the same time points.
Cardiac Catheterization
Transcatheter ASD closure was accomplished through the femoral
vein by using CardioSeal (NMT Medical, Inc, Boston, Mass) in 5
patients and Amplatzer Septal Occluder (AGA Medical Corp,
Golden Valley, Minn) in 10 patients. All patients received 150
U/kg heparin. Hemoglobin levels were not measured after ASD
closure in this study. However, during a separate pilot study,
hemoglobin levels were measured in 6 consecutive patients before
and after ASD device closure.
Samples of exhaled air in patients undergoing closure of the
ASD in the cardiac catheterization laboratory were obtained before
and 30 minutes after the intervention.
Exhaled Gas Analysis
Exhaled air was sampled with a 19-gauge, 12-inch catheter (Bec-
ton Dickinson Vascular Access, Sandy, Utah) tailored to the length
of the endotracheal tube and inserted through the end-tidal carbon
dioxide port. Two consecutive samples of end-tidal expiratory gas
were drawn through the intratracheal catheter into a 20-mL syringe
to minimize airway NO uptake and approximate alveolar NO
levels. Analysis of the specimen was performed with a rapid-
response chemiluminescent analyzer (Sievers 270B, Boulder,
Colo). Calibration of the analyzer was performed daily with serial
dilutions of a standard NO gas.
Ambient air in the operating and cardiac catheterization rooms
measured 2 ppb NO. Exhaled NO in the sealed syringes were
determined within 15 minutes of sampling. We verified that this
technique correlated (5%) with immediate chemiluminescence
measurement, providing samples were analyzed within 1 hour. The
mean of the 2 samples was used for analysis.
All patients were assessed before and after ASD closure by
means of 2-dimensional transesophageal or transthoracic echocar-
diography (pulsed and color flow Doppler examination). Mean
pulmonary artery pressure was estimated from the peak velocity of
the pulmonary insufficiency Doppler signal plus an assumed right
atrial pressure of 5 mm Hg.
Ethical Approval
The research protocol was approved by the Hospital for Sick
Children Human Ethics Committee, and informed consent was
obtained from the subjects or their parents.
TABLE 1. Patient details
Transcatheter ASD closure (n  15) Surgical ASD closure (n  15)
Age (y) Median 8.4 (range 4-17) Median 6.5 (range 0.4-16)
Weight (kg) Median 23.5 (range 16-91) Median 20 (range 5.2-57)
Sex 6 male/9 female 4 male/11 female
ASD size (cm) Median 1.4 (range 0.8-1.9) Median 1.6 (range 0.8-3.0)
No statistically significant difference in age, weight, or ASD size between groups was seen.
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Continuous variables were expressed as means  SD. Within-
group differences were assessed with paired t tests. The differences
between the groups were assessed by comparing the difference or
differences between before and after levels of NO. Analysis of
covariance with adjustment for the preintervention level was used
to compare the percentage change between groups.
Nonparametric testing was used to compare age, weight, and
ASD size between the 2 groups because the data were not normally
distributed. These results were expressed as medians and ranges.
Results
The individual measurements for each patient are shown in
Figure 1. In patients undergoing surgical ASD closure,
exhaled NO decreased by 21%, from 10.9  4.4 to 8.4 
3.3 ppb (P  .005). In contrast, there was a 23% increase in
exhaled NO, from 7.6  2.6 to 9.3  3.7 ppb (P  .005),
in the patients undergoing ASD device closure. Comparison
of the percentage change in exhaled NO levels between
transcatheter and surgical ASD closure was significantly
different (P  .0001).
The preintervention exhaled NO levels were significantly
higher (P  .05) in the surgical compared with in the
transcatheter closure group. However, even with adjustment
for the difference in baseline exhaled NO levels, there
remained a significant difference (P .0001) in the postint-
ervention exhaled NO level between the groups.
CPB time ranged from 14 to 81 minutes (median, 45
minutes; mean, 44.3  18.4 minutes).
Hemoglobin levels in patients undergoing surgical inter-
vention were significantly lower (P  .0001) postopera-
tively (Table 2). Hemoglobin levels were not measured after
transcatheter ASD closure in this study. However, there was
no change in hemoglobin levels before (mean, 123  9.4
g/L) and after (mean, 122  9.0 g/L) device closure in a
different group of patients (n  6). There were no statisti-
cally significant differences between systolic and diastolic
blood pressure, pH, PCO2, PO2, and end-tidal carbon dioxide
between the 2 groups (Table 2).
Heart rate in patients after device closure of the ASD was
slower compared with the initial values and with the heart
rate at the end of the surgical procedure (Table 2).
Body temperature was lower in the surgical group (Table
2).
The mean pulmonary artery pressure estimated by means
of echocardiography before and after ASD closure was
similar in both groups (15  4 mm Hg before and 14  5
mm Hg after closure). Echocardiography revealed no resid-
ual shunt at the end of the operation. A trivial leak across the
device was detected by means of color Doppler scanning in
3 of 15 patients after transcatheter closure.
Discussion
We found that exhaled NO levels decrease in children after
surgical ASD closure undertaken with CPB, despite the fall
in hemoglobin. In contrast, transcatheter ASD closure re-
sults in an increase in exhaled NO levels. We suggest that
endothelial cell dysfunction, rather than the decrease in
pulmonary blood flow after ASD closure, is responsible for
decreased NO production after CPB.
Endogenous NO production after CPB is decreased in
lambs, piglets, and human subjects.5-7 Decreased exhaled
NO levels after hypothermic CPB have been described in
adults, as well as in children, after correction of left-to-right
shunts. Thus our findings are in agreement with those of
previous studies.4,7
Exhaled NO levels may decrease as a result of reduced
NO production or increased NO inactivation. The present
study can not differentiate between these 2 mechanisms.
However, there is evidence that CPB adversely affects en-
dothelial-dependant vasorelaxation and that endothelial dys-
function contributes to postoperative pulmonary hyperten-
sion and microvascular injury that is ameliorated by the
postoperative use of inhaled NO.1,3 The possible contribu-
tion of hypothermia and the heparin-protamine interaction
on exhaled NO levels can not be differentiated from CPB in
the present study.
Hemoglobin decreased after surgical ASD closure. Ex-
haled NO levels increased in exsanguinated rats, and con-
versely, addition of autologous blood to a Krebs-dextran
and albumin perfusion solution decreased exhaled NO in
isolated pig lungs.8,9 The changes that we detected in ex-
haled NO are more compelling because the decrease after
Figure 1. Exhaled NO before and after surgical and transcatheter
ASD closure. Thick black lines, Individual measurements; thin
black lines, means  SD.
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surgical ASD closure occurred with a decrease in hemoglo-
bin.
Although the decrease in exhaled NO levels after surgi-
cal ASD correction with the use of CPB is in agreement
with that seen in previous studies,4,7 we detected a 23%
increase in exhaled NO after transcatheter ASD closure.
This result contrasts with the only other study of exhaled
NO after transcatheter ASD closure, in which there was a
22% decrease in exhaled NO levels.10 The reason for the
discordance in results is unclear and may reflect differences
in exhaled NO sampling techniques (the marked flow de-
pendence of exhaled NO has been demonstrated11) or an-
esthetic agents that may impair endothelial function.12 We
sampled for NO with constant ventilator settings: fraction of
inspired oxygen between 0.25 and 0.3 and isoflurane (which
may impair NO production at concentrations of 2%) kept
at 0.5% to 1% and discontinued for 15 minutes before
sampling.12
Pulmonary blood flow is decreased with either surgical
or transcatheter ASD closure. The findings in the present
study with a decrease in exhaled NO after surgical inter-
vention and an increase after device closure suggest that
exhaled NO levels change independently of pulmonary
blood flow, at least in patients with atrial level shunts and
normal pulmonary artery pressures before and after ASD
closure.
We would suggest 2 possible explanations for the in-
crease in exhaled NO after transcatheter ASD closure. First,
immediately after ASD closure, pulmonary blood flow de-
creases, yet pulmonary artery pressures remain relatively
unchanged if there are low pulmonary artery pressures
before ASD closure. As in the present and other studies,10
the calculated pulmonary vascular resistance must increase
unless there is recruitment of the pulmonary capillary bed.
In the absence of endothelial dysfunction, we suggest that
NO production increases in response to either increased
pulmonary vascular tone or vascular recruitment. Second,
because hemoglobin binds NO avidly,13 a relative paucity in
hemoglobin traversing the pulmonary vascular bed caused
by an abrupt decrease in pulmonary blood flow would
increase free NO levels.
Although high levels of exhaled NO may be measured in
the nasopharynx, all of our patients were intubated, and
contamination from nasal air was excluded. We minimized
the contribution of bronchial NO by sampling with an
intra-airway catheter and taking samples during free exha-
lation to minimize the transit time in the airway and con-
tamination by dead space gas. We verified that inspired NO
levels were always lower than expired levels and excluded
environmental contamination.
There was a significant difference in exhaled NO levels
before ASD closure between the 2 groups. We speculate
that this may be related to surgical stimulation before can-
nulation. However, the consistent change within groups and
the increase in exhaled NO in the transcatheter group com-
pared with the decrease in the surgical group suggest that
the changes are not due to chance or drift to baseline.
It seems likely that in the present study changes in
exhaled NO levels reflect endogenous production by the
pulmonary vascular endothelium, as reported in the isolated
pig lung and in human subjects during CPB.6,7
In conclusion, surgical ASD closure with CPB results in
a decrease in exhaled NO. Decreased exhaled NO levels
may be a marker of pulmonary vascular injury in children
undergoing surgical repair of congenital heart defects. Al-
though the origin of postoperative pulmonary vascular com-
plications is complex and multifactorial, decreased NO pro-
duction may explain the efficacy of inhaled NO therapy of
post-CPB pulmonary hypertension and lung injury. Further-
more, exhaled NO levels may prove useful to monitor the
effect of strategies to minimize endothelial dysfunction and
augment NO production during CPB. In contrast, after
transcatheter ASD closure, exhaled NO levels increase,
suggesting that alterations in pulmonary blood flow are not
primarily responsible for changes in exhaled NO. However,
TABLE 2. Physiologic parameters before and after ASD closure
Before CPB After CPB Before device After device
Hemoglobin (g/L) 123 10 88 12 110 9 NA
Rectal temperature (°C) 35.9 0.7* 35.4 0.7*† 36.4 0.4 36.5 0.7†
Heart rate (beats/min) 112 16 115 19† 105 21* 93 16*†
Systolic blood pressure (mm Hg) 97 11 98 15 103 7 102 10
Diastolic blood pressure (mm Hg) 58 9 55 10 55 7 51 7
pH 7.42 0.07 7.44 0.04 7.38 0.02 NA
Po2 (mm Hg) 235 114 229 93 NA NA
Pco2 (mm Hg) 37 6 38 4 41 5 NA
Etco2 (mm Hg) 38 4 37 3 37 4 37 4
Values are given as means  SD (central venous sample). NA, Not available; Etco2 , end-tidal CO2.
*P  .05 between groups.
†P  .05 within groups.
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after acute reduction in pulmonary blood flow, without a
decrease in pressure, there is an increase in NO production.
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